Hematopoiesis News Volume 13.02 | Jan 18 2022

May 12, 2022

2022-01-18 | HN 13.02

Hematopoiesis News by STEMCELL Technologies

Vol. 13.02 – 18 January, 2022

TOP STORY

Hemolysis Contributes to Anemia during Long-Duration Space Flight

Researchers showed that space flight was associated with persistently increased levels of products of hemoglobin degradation, carbon monoxide in alveolar air and iron in serum, in 14 astronauts throughout their six month missions onboard the International Space Station.
[Nature Medicine]

Full Article Press Release

Dr. Daniel Dever, describes a CRISPR-Cas9-based protocol for gene editing hematopoietic stem cells in this on-demand webinar.

PUBLICATIONSRanked by the impact factor of the journal

TRAF6 Functions as a Tumor Suppressor in Myeloid Malignancies by Directly Targeting MYC Oncogenic Activity

To identify signaling states that cooperate with pre-leukemic cells, the authors used an in vivo RNAi screening approach and identified one of the most prominent genes as the ubiquitin ligase TRAF6.
[Cell Stem Cell]

Abstract Graphical Abstract

PICH Supports Embryonic Hematopoiesis by Suppressing a cGAS-STING-Mediated Interferon Response

Using Pich knock-out mouse models, scientists provided evidence for a mechanistic link between PICH deficiency and defective hematopoiesis.
[Advanced Science]

Full Article

Pre-Configuring Chromatin Architecture with Histone Modifications Guides Hematopoietic Stem Cell Formation in Mouse Embryos

Researchers performed multi-omics dissection of the HSC ontogeny trajectory across early arterial endothelial cells (ECs), hemogenic ECs, pre-HSCs, and long-term HSCs in mouse embryos.
[Nature Communications]

Full Article

HMCES Safeguards Genome Integrity and Long-Term Self-Renewal of Hematopoietic Stem Cells during Stress Responses

Investigators showed that HMCES, a novel shield of abasic sites, played pivotal roles in overcoming the challenge of HSC stress responses upon HSC activation.
[Leukemia]

Abstract

Synergistic Activity of Combined Inhibition of Anti-Apoptotic Molecules in B Cell Precursor ALL

When analyzing the effects of BH3-mimetics selectively targeting BCL-XL and MCL-1 alone or in combination with the BCL-2 inhibitor venetoclax, heterogeneous sensitivity to either of these inhibitors was found in acute lymphocytic leukemia (ALL) cell lines and in patient-derived xenografts.
[Leukemia]

Full Article

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

To mitigate antigen escape and potentially improve the durability of remission, scientists developed a dual-targeting approach using an optimized, bispecific CAR construct that targets both CD19 and BAFF-R.
[Leukemia]

Full Article

HMCES Safeguards Genome Integrity and Long-Term Self-Renewal of Hematopoietic Stem Cells during Stress Responses

Investigators showed that HMCES, a novel shield of abasic sites, played pivotal roles in overcoming the challenge of HSC stress responses upon HSC activation.
[Leukemia]

Abstract

Sorting Nexin 24 Is Required for α-Granule Biogenesis and Cargo Delivery in Megakaryocytes

The authors investigated whether the genes showing abnormal expression in FLI1-deficient platelets could be involved in platelet α-granule biogenesis by undertaking transcriptome analysis of control platelets and platelets harboring a DNA-binding variant of FLI1.
[Haematologica]

Abstract

Novel Inhibitor of Hematopoietic Cell Kinase as a Potential Therapeutic Agent for Acute Myeloid Leukemia

Scientists investigated in vitro, ex vivo and in vivo effects of a novel chemical compound targeting HCK inhibition, in combination with the most used drugs for the treatment of myelodysplastic syndrome and de novo acute myeloid leukemia, 5-Azacytidine and Cytarabine.
[Cancer Immunology Immunotherapy]

Abstract

CLINICAL RESEARCH

Melflufen or Pomalidomide plus Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide (OCEAN): A Randomized, Head-to-Head, Open-Label, Phase III Study

Researchers determined whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma.
[Lancet Haematology]

Abstract

Clinical Outcomes of Individualized Busulfan-Dosing in Hematopoietic Stem Cell Transplantation in Chinese Children Undergoing with Therapeutic Drug Monitoring

Therapeutic drug monitoring and individualization of busulfan dosage were essential to improve the efficacy and safety of busulfan-based regimen in Chinese pediatric hematopoietic stem cell transplantation recipients.
[Bone Marrow Transplantation]

Abstract

Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.

REVIEWS

Lower RNA Expression of ALDH1A1 Distinguishes the Favorable Risk Group in Acute Myeloid Leukemia

Scientists review studies characterizing the role of ALDH1A1 in acute myeloid leukemia and its potential as a therapeutic target.
[Molecular Biology Reports]

Abstract

INDUSTRY AND POLICY NEWS

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-Derived Allogeneic Cell Therapies

Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.
[Century Therapeutics]

Press Release

IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA^® (pembrolizumab) in Patients with r/r DLBCL

IMV Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
[IMV Inc.]

Press Release

FEATURED EVENT

Hemolysis Contributes to Anemia during Long-Duration Space Flight

TRAF6 Functions as a Tumor Suppressor in Myeloid Malignancies by Directly Targeting MYC Oncogenic Activity

PICH Supports Embryonic Hematopoiesis by Suppressing a cGAS-STING-Mediated Interferon Response

Pre-Configuring Chromatin Architecture with Histone Modifications Guides Hematopoietic Stem Cell Formation in Mouse Embryos

HMCES Safeguards Genome Integrity and Long-Term Self-Renewal of Hematopoietic Stem Cells during Stress Responses

Synergistic Activity of Combined Inhibition of Anti-Apoptotic Molecules in B Cell Precursor ALL

CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia

HMCES Safeguards Genome Integrity and Long-Term Self-Renewal of Hematopoietic Stem Cells during Stress Responses

Sorting Nexin 24 Is Required for α-Granule Biogenesis and Cargo Delivery in Megakaryocytes

Novel Inhibitor of Hematopoietic Cell Kinase as a Potential Therapeutic Agent for Acute Myeloid Leukemia

Melflufen or Pomalidomide plus Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide (OCEAN): A Randomized, Head-to-Head, Open-Label, Phase III Study

Clinical Outcomes of Individualized Busulfan-Dosing in Hematopoietic Stem Cell Transplantation in Chinese Children Undergoing with Therapeutic Drug Monitoring

Lower RNA Expression of ALDH1A1 Distinguishes the Favorable Risk Group in Acute Myeloid Leukemia

Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-Derived Allogeneic Cell Therapies

IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA^® (pembrolizumab) in Patients with r/r DLBCL

Cell Therapy Analytics Symposium

> See All Events

Faculty Position – Hematopathology

PhD Student – Chronic Lymphocytic Leukemia

Postdoctoral Positions – Clinical Proteomics

Scientist – CART T Cell Cancer Immunotherapies

Project Manager – Therapeutic Development Branch

> See All Jobs